Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1955 1
1956 1
1962 1
1964 2
1965 2
1966 2
1967 7
1968 7
1969 3
1970 2
1971 2
1972 7
1973 5
1974 3
1975 8
1976 7
1977 9
1978 9
1979 7
1980 7
1981 8
1982 16
1983 12
1984 8
1985 15
1986 8
1987 13
1988 20
1989 30
1990 26
1991 25
1992 34
1993 20
1994 38
1995 39
1996 43
1997 43
1998 46
1999 49
2000 73
2001 76
2002 88
2003 84
2004 87
2005 87
2006 76
2007 87
2008 114
2009 94
2010 115
2011 120
2012 168
2013 176
2014 173
2015 151
2016 152
2017 141
2018 164
2019 148
2020 197
2021 191
2022 180
2023 176
2024 64

Text availability

Article attribute

Article type

Publication date

Search Results

3,392 results

Results by year

Filters applied: . Clear all
Page 1
Evidence-based clinical practice guidelines for inflammatory bowel disease 2020.
Nakase H, Uchino M, Shinzaki S, Matsuura M, Matsuoka K, Kobayashi T, Saruta M, Hirai F, Hata K, Hiraoka S, Esaki M, Sugimoto K, Fuji T, Watanabe K, Nakamura S, Inoue N, Itoh T, Naganuma M, Hisamatsu T, Watanabe M, Miwa H, Enomoto N, Shimosegawa T, Koike K. Nakase H, et al. Among authors: sugimoto k. J Gastroenterol. 2021 Jun;56(6):489-526. doi: 10.1007/s00535-021-01784-1. Epub 2021 Apr 22. J Gastroenterol. 2021. PMID: 33885977 Free PMC article. Review.
Efficacy and Safety of Esaxerenone in Hypertensive Patients with Diabetes Mellitus Undergoing Treatment with Sodium-Glucose Cotransporter 2 Inhibitors (EAGLE-DH).
Motoki H, Inobe Y, Fukui T, Iwasaki A, Hiramitsu S, Koyama S, Masuda I, Sekimura N, Yamamoto K, Sato A, Komatsu M, Taguchi T, Shiosakai K, Sugimoto K, Kuwahara K. Motoki H, et al. Among authors: sugimoto k. Adv Ther. 2023 Nov;40(11):5055-5075. doi: 10.1007/s12325-023-02633-8. Epub 2023 Sep 21. Adv Ther. 2023. PMID: 37733211 Free PMC article.
Annual reports on hypertension research 2020.
Mogi M, Higashi Y, Bokuda K, Ichihara A, Nagata D, Tanaka A, Node K, Nozato Y, Yamamoto K, Sugimoto K, Shibata H, Hoshide S, Nishizawa H, Kario K. Mogi M, et al. Among authors: sugimoto k. Hypertens Res. 2022 Jan;45(1):15-31. doi: 10.1038/s41440-021-00766-3. Epub 2021 Oct 15. Hypertens Res. 2022. PMID: 34650193 Review.
The claudin-transcription factor signaling pathway.
Sugimoto K, Chiba H. Sugimoto K, et al. Tissue Barriers. 2021 Jul 3;9(3):1908109. doi: 10.1080/21688370.2021.1908109. Epub 2021 Apr 27. Tissue Barriers. 2021. PMID: 33906582 Free PMC article. Review.
Editorial: Oxylipins: The Front Line of Plant Interactions.
Sugimoto K, Allmann S, Kolomiets MV. Sugimoto K, et al. Front Plant Sci. 2022 Mar 28;13:878765. doi: 10.3389/fpls.2022.878765. eCollection 2022. Front Plant Sci. 2022. PMID: 35419016 Free PMC article. No abstract available.
In silico-labeled ghost cytometry.
Ugawa M, Kawamura Y, Toda K, Teranishi K, Morita H, Adachi H, Tamoto R, Nomaru H, Nakagawa K, Sugimoto K, Borisova E, An Y, Konishi Y, Tabata S, Morishita S, Imai M, Takaku T, Araki M, Komatsu N, Hayashi Y, Sato I, Horisaki R, Noji H, Ota S. Ugawa M, et al. Among authors: sugimoto k. Elife. 2021 Dec 21;10:e67660. doi: 10.7554/eLife.67660. Elife. 2021. PMID: 34930522 Free PMC article.
3,392 results